Key result
This review considers the role of inhibition of the cytokine tumour necrosis factor in the symptomatic and prognostic treatment of patients with heart failure.
Why the study?
Does inhibition of the cytokine tumour necrosis factor have therapeutic potential in patients with heart failure?
Does inhibition of the cytokine tumour necrosis factor have therapeutic potential in patients with heart failure?
This review discusses the potential therapeutic role of anti-inflammatory interventions, specifically tumour necrosis factor inhibition, in the treatment of heart failure.
TNF inhibition in heart failure remains investigational; leaves open whether anti-inflammatory strategies improve symptoms or prognosis.
Heart failure is a systemic disorder characterised by tissue hypoxia and secondary organ dysfunction which occurs in response to various myocardial insults that include ischaemia, viral infections, and toxins. In addition to maladaptive neurohumoral activation, heart failure is associated with an inflammatory state that appears to have a detrimental effect on cardiac function and prognosis. This has led to the suggestion that anti-inflammatory interventions may have therapeutic potential in the symptomatic and prognostic treatment of patients with heart failure. This review considers the role of inhibition of the cytokine tumour necrosis factor in the treatment of heart failure. . . . . . . . . .
No takes yet. Share an insight, caveat, or question.
Satoshi Kurisu (2002) conducted a review in Heart failure. Inhibition of the cytokine tumour necrosis factor was evaluated. This review considers the role of inhibition of the cytokine tumour necrosis factor in the symptomatic and prognostic treatment of patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: